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NSAID use did not have an increased risk (stage 2 OR 1.002, CI 0.925-1.086; stage 3
OR 0.936, CI 0.782-1.122) of rapid CKD progression compared to the no NSAID ex-
posure group. Stage 2-3 CKD patients with high NSAID use trended toward, but did
not achieve a statistically significant increased risk (stage 2OR 1.185, CI 0.994-1.413;
stage 3 OR 1.276, CI 0.844-1.927) of rapid CKD progression. CONCLUSIONS: NSAID
exposure over a two year period was not associated with an increased risk of renal
dysfunction in our cohort of elderly patients with either stage 2 or 3 CKD.
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OBJECTIVES: To assess the prescribing, switching, and dose-adjustment patterns
of overactive bladder (OAB) drugs in a real-world patient population.METHODS: A
retrospective analysis was conducted using the Medstat Marketscan databases,
which contain pharmacy claims for 28 million individuals across the US. Study
patients received anOAB drug prescription between April 1, 2009 and April 30, 2010
with continuous enrollment 6 months before the index date. Demographics, diag-
nosis rate, prescription fill dates, patients who switched to or from a given OAB
drug, and patients adjusting dosage were evaluated. RESULTS: A total of 214,721
patients had anOABprescription (mean age 65 y, 76%women), 23%were diagnosed
with OAB; 37% of patients resided in Southern, 35% in Northern Central, 18% in
Western, and 9% in Northeastern regions of the United States. Many patients
switched drug therapy during the study period; those receiving drugswithmultiple
dose options appeared to have oftenmade dose adjustments rather than switching
to a new agent (Table). For example, among patients prescribed solifenacin, 22% of
switches were to increase the dose and 39% were to decrease the dose. The pro-
portion of patients switching to another agent was higher among those receiving
oxybutynin, tolterodine ER, and solifenacin than with fesoterodine, darifenacin,
and trospium. Among 32,782 (15%) patients who switched OABmedication at least
once, the median (range) duration of time between filling their initial prescription
and either dose-adjusting or switching to a new agent was 139 (0–393) days and
they filled a median (range) of 4 (2–41) prescriptions before dose-adjusting or
switching. CONCLUSIONS: In this real-world population, patients take advantage
of the ability to adjust between multiple doses of drugs for which a flexible-dose
treatment option is available. Many patients switched drug therapy, which sug-
gests an opportunity to improve management of these patients and to identify an
optimal treatment pathway.
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OBJECTIVES: In patients undergoing chronic hemodialysis, unfractionated heparin
(UFH) is widely used for prevention of extracorporeal circuit thrombosis. Low-
molecular-weight heparin (LMWH)may have advantages in terms of bleeding risk.
The objective of this study was to review the effectiveness, safety and cost-effec-
tiveness of LMWH versus UFH in chronic hemodialysis to inform a hospital formu-
lary policy decision.METHODS:A systematic reviewwas conducted of randomized
(RCTs) and non-randomized trials (non-RCTs) published to April 2010 evaluating
the effectiveness, safety or cost-effectiveness of LMWHs for use in hemodialysis
compared with UFH. Outcomes included extracorporeal circuit thrombosis, bleed-
ing events, vascular access compression time, heparin-induced thrombocytope-
nia, and cost-effectiveness. Where possible, data was pooled via a random-effects
model. RESULTS:After reviewing 998 citations, 25 studieswere included (1 system-
atic review, 12 RCTs, 12 non-RCTs). Meta-analysis of RCTs demonstrated no statis-
tically significant differences between LMWH and UFH for bleeding (relative risk
(RR)0.70, p0.66) or compression time (weighted mean difference 2.49,
p0.31). Pooled RR for circuit thrombosis was 1.32 (p0.05) and 0.67 (p0.69) in
studies assessing the number of dialysis session and patients, respectively. Pooled
results for the non-RCTs were not significantly different between LMWH and UFH.
No studies evaluating the cost-effectiveness of LMWH versus UFH were identified,
however 4 cost analyses evaluated treatment costs. Despite higher drug acquisi-
tion costs with LMWH, overall costs were lower or comparable when considering
differences in nursing time associated with administration and monitoring.
CONCLUSIONS: LMWHdemonstrated no clear advantage over UFH in terms of effec-
tiveness or safety, but may result in lower or comparable overall hospital costs.
Urinary/Kidney Disorders – Cost Studies
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) is a common complication of
chronic kidney disease (CKD). Cinacalcet is a drug that can regulate the levels of
plasma PTH, serum calcium and phosphorus in patients not controlled with stan-
dard treatment (vitamin D sterols and phosphate binders).We evaluated the use of
cinacalcet vs. standard treatment from a Public Mexican Healthcare perspective.
METHODS: A cost-effectiveness and a budget impact analyses were performed
with a simulation model over the whole patient=s lifetime considering 8-weeks
cycles. Efficacy data of cinacalcet were taken from published literature. Local mor-
tality data was adjusted for levels of Ca, P and PTH and for Relative Risk (RR) of
death in dialysis patients. Events considered are cardiovascular events, fractures
and parathyroidectomy. Costs are evaluated in local setting and account for drugs,
dialysis procedures and events. Patients were considered in the budget impact
(BIA) with a predicted uptake of cinacalcet in public sector of 7% in the first year.
RESULTS: The simulated patients in the cinacalcet group with respect to standard
treatment group experienced a mean (SD) increase in the average time in range
(TiR) of 1.91 (4.04) patient-years on all parameters and a lower rate of hospitaliza-
tion: RR were 0.43, 0.82 and 0.96 respectively for PTX, fracture and cardiovascular
hospitalization. Considering a price for the public sector of $ 3.29MXP /mg, the
average ICER for all parameters resulted $210,060MXP / TiR. BIA with cinacalcet
price for public sector predicted an extra expenditure of approximately $8 MXP
million in the first year considering drug costs and it represented the 0.2% of the
total health care expenditure for CKD. CONCLUSIONS: The use of cinacalcet in
comparison with standard treatment is a cost-effective strategy in patients with
SHPT and its use implies a low economic impact as compared to the total health-
care expenditure assigned to CKD in Mexico.
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OBJECTIVES: The objective of this study was to estimate resource use and associ-
ated costs of care among recipients of kidney transplant according to donor type,
from the perspective of the Brazilian Public Health System (SUS). METHODS: The
KIT73 study was a retrospective observational study conducted at 7 transplant
centers, including 498 adult single kidney only transplant recipients from Jan/2004
to Jan/2005. Recipients were identified by donor type (living (LD) or deceased (DD)).
The DD group was further stratified by standard criteria donors (SCD) or expanded
criteria donors (ECD). Five-year costs were adjusted to 2004 at an annual discount
rate of 5% and converted to 2010 USD. A casemix group costing approachwas used
to determine average costs per day of hospitalization, stratified by cause (surgical
or clinical complication) and type (general ward, Intensive Care Unit (ICU).
RESULTS: All 498 recipients were included in the analyses. For both groups (LD or
DD), total inpatient costs of care were higher than total outpatient costs (excluding
medications) at 1 and 5 years. LD recipients incurred significantly lower costs than
DD recipients: mean (SD) costs per patient were USD1,460 (USD1,813) (LD) v0.s
USD2,785 (USD 3,615) (DD) (p0.0001) in the first year; USD288 (USD599) (LD) vs.
USD568 (USD1,540) (DD) (p0.01) in the fifth year. Comparison between SCD and
ECD groups, however, showed that the mean (SD) costs per patient were USD2,692
(USD3,616) (SCD) vs. USD3,767 (USD5,481) (ECD) (p0.377); USD545 (USD1,540) (SCD)
vs. USD810 (USD1,117) (ECD) (p0.146) in the fifth year. CONCLUSIONS: Recipients
of kidney transplants from living donors had lower costs over five years as com-
pared to recipients of transplants from deceased donors. Among recipients from
deceased donors, no statistical difference was observed in the comparison be-
tween ECD and SCD recipients.
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OBJECTIVES: The objective of this research was to estimate expenditures attribut-
able to chronic kidney disease (CKD) by disease stage and to identify predictors of
variation in spending. METHODS: A retrospective analysis of de-identified health
insurance claims, laboratory data and pharmacy claims was performed using the
MarketScan Lab Results database for 2007. We calculated estimated glomerular
filtration rates (eGFR) using the 4 variable modification of diet and renal disease
(MDRD) equation and defined cases as those with an eGFR60mL/min/1.73m2.
Presence of comorbid conditions was base on ICD-9 codes reported on the claims.
Propensity score methods were used to match controls to cases. Data were ana-
lyzed using descriptive statistics and generalized linear models with a gamma
distribution and log-link controlling for disease stage, health plan type, comorbid
conditions, and demographic characteristics. RESULTS: A total of 2,436 cases were
identified with an eGFR of less than 60mL/min/1.73m2. We were able to match
controls to 2,223 (91.3%) of the identified CKD cases using propensity scores. Un-
adjusted expenditures were $10,353 (sd 23,262) for CKD cases compared to $9,310
(sd 22,703) for matched controls. After adjusting for health plan type, patient de-
mographic characteristics, and comorbid conditions, adjusted expenditures were
significantly greater for patients with CKD compared to matched controls depend-
ing on CKD stage. Expenditures by stage ranged from 8% higher for patients with
stage 3 disease to 62% higher for patients with stage 5 CKD compared to matched
controls. The key predictors of total treatment payments were disease stage, pres-
ence of comorbid conditions, age, and gender. CONCLUSIONS: Payments for med-
ical care attributable to CKD are significantly greater than medical care payments
for those who do not have CKD and vary importantly by disease stage. Interven-
tions that prevent or delay the progression of CKD have the potential to save
considerable resources.
A75V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
